Sarbecovirus

Study finds schools are not at higher risk for COVID-19

Retrieved on: 
Tuesday, June 22, 2021
Coronaviridae, Medicine, Health sciences, Sarbecovirus, Zoonoses, Epidemiology, Infectious diseases, Occupational safety and health, COVID-19, Severe acute respiratory syndrome, Subclinical infection, COVID-19 testing

Even when we account for asymptomatic infection using sensitive blood tests, the risk of SARS-CoV-2 being transmitted in schools overall remains very low, says Dr. David Goldfarb, co-investigator and lead author of the article.

Key Points: 
  • Even when we account for asymptomatic infection using sensitive blood tests, the risk of SARS-CoV-2 being transmitted in schools overall remains very low, says Dr. David Goldfarb, co-investigator and lead author of the article.
  • In this study, school staff reported consistent rates of positive viral tests which are similar to the Vancouver School District1.3 per cent.
  • These results reaffirm that with the protocols we have in place, schools are safe places to teach and learn.
  • This study highlights that COVID-19 in a school setting typically mirrors transmission from family and community contacts.

Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)

Retrieved on: 
Monday, June 21, 2021
Medicine, Medical specialties, Health, Sarbecovirus, COVID-19, Long Covid, Fibromyalgia, Tonix Pharmaceuticals, Severe acute respiratory syndrome coronavirus, Sleep disorder, PASC, Fatigue

Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID, or PASC.

Key Points: 
  • Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID, or PASC.
  • Most Long COVID patients who have been studied appear to have cleared the SARS-CoV-2 virus from their systems.
  • By improving sleep quality, we believe TNX-102 SL may improve the sleep disturbance of Long COVID and potentially also improve other symptoms of Long COVID.
  • For example, TNX-102 SL showed activity in addressing persistent pain, sleep disturbance and fatigue in our fibromyalgia Phase 3 study.

Bio-Rad Launches Its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit for COVID-19 Wastewater Testing

Retrieved on: 
Monday, June 21, 2021
Health, Infectious diseases, Utilities, Other Health, Energy, Biotechnology, Sarbecovirus, Zoonoses, Animal diseases, Branches of biology, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Real-time polymerase chain reaction, Wastewater-based epidemiology

ddPCR technology is recommended in the Centers for Disease Control and Prevention guidelines (CDC) for wastewater testing, and use of the technology has been published by the Environmental Protection Agency (EPA) as a dependable method to quantify viruses in wastewater.

Key Points: 
  • ddPCR technology is recommended in the Centers for Disease Control and Prevention guidelines (CDC) for wastewater testing, and use of the technology has been published by the Environmental Protection Agency (EPA) as a dependable method to quantify viruses in wastewater.
  • The PREvalenceddPCR SARS-CoV-2 Wastewater Quantification Kit includes all reagents needed to detect the virus in wastewater along with software for automated analysis.
  • Other products include molecular qPCR and ddPCR instruments and assays, antibody tests, quality controls, and ddPCRassays to detect SARS-CoV-2 variants of concern.
  • BIO-RAD, PREVALENCE, DROPLET DIGITAL, DDPCR, QX200, AUTODG and QX ONE are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

PERFORMACIDE® Kills Virus Causing COVID-19 In Just 30 Seconds

Retrieved on: 
Tuesday, June 22, 2021
Sarbecovirus, Respiratory diseases, Animal diseases, Medical specialties, Zoonoses, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Disinfectant

Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.

Key Points: 
  • Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.
  • To prove efficacy, PERFORMACIDE was tested directly against the SARS-CoV-2 (COVID-19) virus.
  • CEO and President, Peter Dornau, commented, "Killing the virus that causes COVID-19 in under a minute will dramatically expand the markets for PERFORMACIDE and its sub-registered brands.
  • Mr. Dornau concluded, "PERFORMACIDE already reduces the many steps involved in a full cleaning routine by eliminating rinsing or wiping again.

Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium

Retrieved on: 
Friday, June 18, 2021
Coronaviridae, Sarbecovirus, Health sciences, Medicine, Zoonoses, Antiviral drugs, COVID-19 pandemic in Russia, Coronavir, Severe acute respiratory syndrome, Brilacidin, COVID-19

The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.

Key Points: 
  • The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.
  • The presentation on Brilacidin will be part of the Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases Breakout Session.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.

Clean Republic Announces SARS-CoV-2 (Covid-19 Virus) 60-Second Kill Claim

Retrieved on: 
Thursday, June 17, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Bactericides, Disinfectant, Hygiene, Animal diseases, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

The announcement comes after testing and resubmission to the EPA and replaces the prior 10-minute kill claim.

Key Points: 
  • The announcement comes after testing and resubmission to the EPA and replaces the prior 10-minute kill claim.
  • At 60 seconds, the Clean Republic Disinfectant + Sanitizer is now one of the fastest acting products on the market for use against SARS-CoV-2.
  • At 60 seconds, Clean Republic Disinfectant + Sanitizer is one of the fastest acting products for use against SARS-CoV-2.
  • "We are proud of the work of our innovations team and this milestone claim from the EPA," said Jake Piccoli, Co-founder and President of Clean Republic.

Two Days Left to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC

Retrieved on: 
Thursday, June 17, 2021
Legal, Professional services, Sarbecovirus, Animal diseases, Health, Directorate-General for Health and Food Safety, Severe acute respiratory syndrome coronavirus 2, European Centre for Disease Prevention and Control, Severe acute respiratory syndrome

Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/ebs .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/ebs .
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
  • or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in Emergent you have until June 18, 2021 to request that the Court appoint you as lead plaintiff.

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

Retrieved on: 
Tuesday, June 15, 2021
Sarbecovirus, Respiratory diseases, Medical specialties, Animal diseases, COVID-19, Occupational safety and health, Public health, Zoonoses, Severe acute respiratory syndrome, Antiviral drug, TLR2

The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.

Key Points: 
  • The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
  • The milestone-based financing round was jointly led by Australian life science investors Brandon Capital Partners and Minderoo Foundation, with co-investment from Uniseed.
  • We recognize that in addition to vaccines, the world needs safe, convenient, broad-spectrum anti-viral therapies to win the fight against COVID-19, said Chris Smith, Ph.D., Chairman of ENA Respiratory.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Retrieved on: 
Monday, June 14, 2021
Coronaviridae, Sarbecovirus, Antiviral drugs, Branches of biology, Health sciences, Zoonoses, 3C-like protease, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, Remdesivir, COVID-19, RNA-dependent RNA polymerase

CDI-45205 and its analogs showed excellent antiviral activity against both SARS-CoV-2 variants, surpassing the activity observed with SARS-CoV-2 (Wuhan strain).

Key Points: 
  • CDI-45205 and its analogs showed excellent antiviral activity against both SARS-CoV-2 variants, surpassing the activity observed with SARS-CoV-2 (Wuhan strain).
  • Two reference inhibitors including remdesivir, an FDA-approved SARS-CoV-2 RNA-dependent RNA polymerase inhibitor, and PF-00835231, another SARS-CoV-2 3CL protease inhibitor, were included in the study as comparators.
  • We are highly encouraged by these results with CDI-45205 against SARS-CoV-2 and two prominent variants of SARS-CoV-2, and we intend to continue with further testing for antiviral activity against other emerging variants including the Indian variant, said Sam Lee, Ph.D., Cocrystals President and interim co-CEO.
  • We believe these new data suggest our protease inhibitor may be an effective treatment of COVID-19 caused by SARS-CoV-2 and its emerging variants.

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

Retrieved on: 
Friday, June 11, 2021
Amino acids, Variants of SARS-CoV-2, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Zoonoses, Vaccine, Protein, Tyrosine

(*2) Subject microorganisms: SARS-CoV-2 (3 strains above) provided by the National Institute of Infectious Diseases.

Key Points: 
  • (*2) Subject microorganisms: SARS-CoV-2 (3 strains above) provided by the National Institute of Infectious Diseases.
  • In this study, the one purchased from the JCRB Cell Bank, the National Institutes of Biomedical Innovation, Health and Nutrition, was used.
  • (*6) N501Y variant: 501st amino acid of S protein is replaced from aspartic acid (N) to tyrosine (Y).
  • Compared to the conventional strains, this variant may work as a stronger suppressor of the immune system and vaccination efficiency.